Purpose: To evaluate the role of topical umbilical cord serum (TUCS) therapy in treating corneal epithelial defects (CEDs) after diabetic vitrectomy. Methods: In this double-masked, randomized clinical trial, we included 80 eyes of 80 patients who were candidates for vitrectomy due to proliferative diabetic retinopathy complications. In cases of corneal edema obscuring the fundus view during surgery, the corneal epithelium was removed using a 6-mm trephine and a blade no.15. The day after the surgery, patients were randomly divided into two groups: (1) the TUCS group that received 20% TUCS six times/day in addition to the conventional treatment of CED and (2) the control group, which was prescribed artificial tears as placebo in addition to the conventional treatment of CED. The rate of healing of CEDs was measured via two maximum linear dimensions perpendicular to each other at the start of therapy and on postoperative days 1–5, 7, and 12. Results: Of 80 eyes, 40 were assigned to each treatment group. The mean times to complete CED healing were 2.4 ± 0.7 and 3.8 ± 2.1 days in the TUCS and control groups, respectively (P < 0.001). Persistent CED occurred in two eyes in the control group but in no eyes in the TUCS group. Conclusion: TUCS therapy may be safe and effective in healing CEDs after vitrectomy in patients with diabetes.

Background: The Lenstar LS 900 (Haag-Streit AG, Koeniz, Switzerland) is an optical biometer, and its measurements are highly repeatable and precise in cataractous eyes. This study investigated changes in biometric parameters, including axial length (AL), anterior chamber depth (ACD), lens thickness (LT), vitreous cavity depth (VD), and central corneal thickness (CCT) before and after three-port 23-Gauge pars plana vitrectomy with silicone oil tamponade. Methods: This was a prospective follow-up study. Patients who were scheduled for surgery underwent a detailed slit-lamp examination and objective cycloplegic refraction preoperatively. In eligible cases, the Lenstar LS 900 was used to measure biometric parameters. At the 1-month postoperative follow-up, we repeated the same assessments for the silicone oil (SO)-filled eyes. Data were analyzed to assess the significance of changes and to test the possible correlation of values between the two time points. Results: Twenty-three patients with a mean ± SD age of 60 ± 12 years completed the study. Postoperatively, we found a significant increase in AL and a decrease in ACD and CCT (all P < 0.05), with no significant changes in LT and VD. A significant correlation was found for ACD, CCT, and cylinder values between the two time points (all P < 0.05). Postoperatively, the spherical and cylindrical components of refraction demonstrated a hyperopic shift, but did not change statistically significantly. Conclusions: The Lenstar LS 900 underestimated the ACD and overestimated the AL in SO-filled eyes when comparing pre- and postoperative values, in phakic as well as pseudophakic eyes. In planning for cataract surgery in this group of patients, it is more reasonable to calculate IOL power based on the biometric data of the fellow eye, although this may not eliminate possible errors. Further studies with a larger sample size, longer follow-up, and robust study design are necessary to confirm our preliminary results.